BioCentury
ARTICLE | Company News

AcelRx's Dsuvia gets CRL

October 12, 2017 10:34 PM UTC

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) sank $3.20 (60%) to $2.15 after FDA issued a complete response letter for its NDA for Dsuvia sufentanil sublingual tablet (ARX-04) to treat moderate-to-severe acute pain in medically supervised settings. The CRL is the second the company has received for a sublingual formulation of sufentanil.

AcelRx said FDA requested additional data on at least 50 patients to assess Dsuvia's safety at the proposed maximum dose and recommended a human factors study to validate changes to its directions for use. The company hopes to meet with FDA concerning a resubmission...

BCIQ Company Profiles

Talphera Inc.